A5009003698- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- HER2/EGFR in Cancer Research
- Click Chemistry and Applications
- Quinazolinone synthesis and applications
- Gastrointestinal Tumor Research and Treatment
- Fungal Plant Pathogen Control
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Microtubule and mitosis dynamics
- PI3K/AKT/mTOR signaling in cancer
- Monoclonal and Polyclonal Antibodies Research
- Hematological disorders and diagnostics
- Platelet Disorders and Treatments
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Genomic variations and chromosomal abnormalities
- Chemotherapy-induced cardiotoxicity and mitigation
Policlinico San Matteo Fondazione
2021-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2021-2024
University of Bologna
2014-2023
Policlinico S.Orsola-Malpighi
2013-2023
Istituto di Ematologia di Bologna
1985-2022
University of Pavia
2021
Azienda USL di Bologna
2020
Istituto Oncologico Romagnolo
2000-2019
University of Bari Aldo Moro
2007-2016
Abstract Purpose: ABL kinase domain mutations have been implicated in the resistance to BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. Experimental Design: Using denaturing high-performance liquid chromatography and sequencing, we screened for 370 Ph+ patients with evidence hematologic or cytogenetic imatinib. Results: Mutations were found 127 297 (43%) evaluable 27% chronic-phase (14% treated frontline; 31% post-IFN failure), 52% accelerated-phase...
Point mutations within the ABL kinase domain of BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients. To shed further light on frequency, distribution, and prognostic significance mutations, we retrospectively analyzed a homogeneous cohort late phase CML patients who showed primary cytogenetic imatinib.Using denaturing high-performance liquid chromatography (D-HPLC) sequencing, screened for total 178 bone marrow and/or...
Abstract Imatinib has now been in use for almost 10 years. Despite this cumulative experience, little is known about its effects on pregnancy; as a result, there are few published data to facilitate the counseling of women who conceive while taking imatinib. The results we present provide information which may be such circumstances. Of 180 exposed imatinib during pregnancy, outcome available 125 (69%). those with outcomes, 50% delivered normal infants and 28% underwent elective terminations,...
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust durable responses at 45 mg/day in patients CP-CML resistant second-generation TKIs PACE trial. However, cardiovascular toxicities, arterial occlusive events (AOEs), have emerged as treatment-related AEs within this class of TKIs. The OPTIC trial evaluated efficacy...
Purpose Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy patients CML-AP who experienced treatment failure imatinib. We now report follow-up data from the full patient cohort 174 enrolled onto II trial provide more complete assessment safety dasatinib this population. Methods imatinib-resistant (n = 161)...